risk-of-paradoxical-eczema-in-patients-receiving-biologics-for-psoriasis 2023-12-07T16:33:00.729Z 3665f6cd-25c6-4c1b-9a81-3f61a93a68e4 mas_evidence_types:Other%20primary%20research Primary research In cohort study (n=13,699 with 24,997 biologic exposures), 273 exposures (1%) were linked to paradoxical eczema (PEZ), with lowest risk in patients on IL-23 inhibitors vs. other biologics. Increasing age, history of atopic dermatitis, & hay fever linked to higher risk of PEZ. <p>Adjusted incidence rates were:</p> <ul> <li>1.22 per 100 000 person-years for IL-17 inhibitors</li> <li>0.94 per 100 000 person-years for TNF inhibitors</li> <li>0.80 per 100 000 person-years for IL-12/23 inhibitors</li> <li>0.56 per 100 000 person-years for IL-23 inhibitors</li> </ul> <p>Compared with TNF inhibitors, IL-23 inhibitors were associated with a lower risk (HR 0.39; 95% CI, 0.19-0.81), and there was no association of IL-17 inhibitors or IL-12/23 inhibitors with risk of paradoxical eczema.</p> https://www.medicinesresources.nhs.uk/risk-of-paradoxical-eczema-in-patients-receiving-biologics-for-psoriasis.html https://jamanetwork.com/journals/jamadermatology/fullarticle/2812208 2023-12-06T00:00:00Z 2023-12-07T16:31:33.379Z